Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct.

BMC biotechnology - 24 Mar 2011

Jimenez Anne-Sophie, Gressette Mélanie, Barjon Clément, Wei Ming, Gourzones Claire, Busson Pierre

Abstract excerpt

BACKGROUND: Bioluminescent tumor cell lines are experimental tools of major importance for cancer investigation, especially imaging of tumors in xenografted animals. Stable expression of exogenous luciferase in tumor cells combined to systemic injection of luciferin provides an excellent signal/background ratio for external optical imaging. Therefore, there is a need to rationalize and speed up the production of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD2 Antigens
Share to HEK293 Cells
Share to HeLa Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Luciferases

Share to Luminescent Measurements

Share to Mice, Nude

Share to Neoplasms, Experimental

Share to Transplantation, Heterologous

Source

Open in PubMed Open full text

Identifiers

PMID: 21435248
DOI: 10.1186/1472-6750-11-26
PMCID: PMC3078863

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct.PMID 21435248Read ↗

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapiesSemantic proximity Read ↗

A dual-luciferase bioluminescence system for the assessment of cellular therapiesSemantic proximity Read ↗

T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancerSemantic proximity Read ↗

Generation of Murine Carcinoma Models with Functional Heterologous HER1 and/or HER2 Receptors for In Vivo Study of Specific TherapiesSemantic proximity Read ↗

A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivoSemantic proximity Read ↗

T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody FragmentSemantic proximity Read ↗

Production of Recombinant Human EGFR CR2 Domain and Generation of Monoclonal Antibodies Discriminating The R and K Variants.Semantic proximity Read ↗

Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation of 89 Zr-Ivuxolimab, a Human OX40 PET TracerSemantic proximity Read ↗

Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emissionSemantic proximity Read ↗

A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.Semantic proximity Read ↗

Advantage of the F(ab)’2 fragment over IgG for RIT and PRITSemantic proximity Read ↗

Low-Background Cancer Imaging With a Bioorthogonal Fluorescence Probe and Engineered Reporter Enzyme Bearing a Targeting MoietySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.